immunotherapy
-
August 7, 2020
Clinical Challenges: Platinum-Resistant Ovarian Cancer Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 12, 2019
Novel Agents Influence the Development of New Strategies for Treatment of Bladder Cancer Bookmark
George Lundberg, MDArticle from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Once bladder cancer has infiltrated the muscle wall in elderly patients, it becomes challenging to treat. New drugs and immunotherapies show some promise.
Go to full article published by Targeted Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 4, 2019
Using Molecular Testing to Guide Treatment for Advanced Colorectal Cancer
With:A Q&A with Kalpana Kannan, PhD, former Scientist at Cancer Commons Q: Colorectal cancer is common, and although many cases in earlier stages are cured by surgery alone or with adjuvant chemotherapy, it is still a lethal threat for many patients. Nonetheless, several new targeted and immunotherapeutic agents are now available. When should patients receive molecular testing for their colorectal cancer, what information should… Read more »
-
May 21, 2019
Can You Improve Your Response to Certain Immunotherapy Drugs?
Emma Shtivelman, PhDCancer treatments that use a strategy called immune checkpoint blockade (ICB) have entered clinical practice in a big way, with six drugs now approved by the U.S. Food and Drug Administration (FDA) for a variety of cancers. These drugs release “brakes” on the immune system, boosting its ability to kill cancer cells. Specifically, they target the proteins PD-1 or CTLA-4, which are found on… Read more »
-
April 8, 2019
New Study Suggests Diet May Affect Response To Cancer Immunotherapy Drugs Bookmark
Emma Shtivelman, PhDExcerpt:
“People with a type of skin cancer who consumed a high-fiber diet responded better to immunotherapy treatment than those with poorer diets, according to data presented at a media preview of the American Association for Cancer Research (AACR) annual meeting.
“Melanoma is a type of skin cancer which although very treatable if caught early, still kills approximately 9,000 Americans a year, mainly people who are diagnosed a more advanced stage of disease where the cancer has spread to other parts of the body.”
Go to full article published by Forbes on Feb 27, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 3, 2019
What’s New in Melanoma Treatment in 2019?
Emma Shtivelman, PhDIt has been over a year since I last wrote about new developments in treatment of melanoma, and it is time for an update. There is certainly some good news for melanoma patients! Neoadjuvant (before surgery) treatments for resectable melanoma Stage III—and more rarely, stage IV—melanoma tumors that have not spread widely can be sometimes treated surgically. Last year a small clinical trial showed… Read more »
-
January 12, 2019
Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer Bookmark
George Lundberg, MDResearch paper from the Journal of the National Comprehensive Care Network curated by Editor in Chief George Lundberg, MD, who notes:
Metastatic or advanced cervical cancer remains very difficult to treat. Immunotherapy is showing promise.Go to full article published in the Journal of the National Comprehensive Care Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 7, 2019
Immune Cells Track Hard-To-Target Brain Tumours Bookmark
Emma Shtivelman, PhDExcerpt:
“Instructing the immune system to recognize and kill tumours, an approach termed cancer immunotherapy, has transformed the clinical treatment of certain types of malignancy. Prominent among these therapies are immune-checkpoint inhibitors, which block the action of proteins that dampen immune-cell responses against tumours. For example, antibodies can be used to interfere with the inhibitory protein PD-1, which is present on T cells, a type of immune cell that attacks tumours. Immune-checkpoint inhibitors have been most successfully used to treat cancers, such as melanomas, that are well infiltrated by T cells and have a large number of genetic mutations. A subset of these mutations might generate neoantigens — altered protein sequences that are uniquely produced in cancer cells and are recognized as foreign by the immune system.”
Go to full article published by Nature on Dec 19, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 7, 2019
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research Bookmark
Emma Shtivelman, PhDExcerpt:
“In a new study by Yale Cancer Center, scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets. The findings are published today in the journal Cell.
“Researchers around the world have been racing to create therapies that unleash the power of our immune systems against cancer. The most successful of these immunotherapies, which target a molecular pathway known as PD-1/PD-L1, have brightened the landscape for many people suffering with lung cancer and other types of tumors.”
Go to full article published by Yale Cancer Center on Dec 20, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.